Novavax (NVAX) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Novavax (NVAX) over the past year, gaining 37.6% versus a gain of 21.7%. Over five years, TRVI leads with a +918.6% price change compared with -93.1% for NVAX. Trevi Therapeutics is the larger company by market cap ($1.87 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVAX | TRVI |
|---|---|---|
| Share price | $10.93 | $13.15 |
| Market cap | $1.80B | $1.87B |
| 1-day change | -2.58% | +0.08% |
| YTD return | +66.96% | +4.95% |
| 1-year return | +21.69% | +37.59% |
| 5-year return | -93.07% | +918.60% |
| EPS (TTM) | $-1.58 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.39 | $20.22 |
| 52-week low | $6.20 | $9.28 |
| Distance from 52-week high | -18.37% | -34.97% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +28.09% | +114.30% |
| Average volume | 5.16M | 1.95M |
| Shares outstanding | 164.95M | 142.48M |
| Employees | 749 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed NVAX by 15.9 percentage points over the past year.
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
NVAX vs TRVI FAQ
Which is bigger, Novavax or Trevi Therapeutics?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.87B compared with $1.80B for Novavax (NVAX).
Which stock has performed better over the past year, NVAX or TRVI?
TRVI returned +37.59% over the past 12 months, compared with +21.69% for NVAX (price return, excluding dividends). Past performance does not predict future results.
Are Novavax and Trevi Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Novavax and Biotechnology: Pharmaceutical Preparations for Trevi Therapeutics.